PL-8177 is under clinical development by Palatin Technologies and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect PL-8177’s likelihood of approval (LoA) and phase transition for Ulcerative Colitis took place on 15 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their PL-8177 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

PL-8177 overview

PL-8177 is under development for the treatment of Inflammatory bowel disease such as ulcerative colitis, nephritis, non-infectious intermediate, posterior, pan, and non- infectious chronic anterior uveitis, diabetic retinopahty, lung fibrosis, and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered subcutaneously and orally. The drug candidate acts by targeting the melanocortin receptor-1 (MC1R).

It was also under development for the treatment of dermatological diseases and Inflammation.

Palatin Technologies overview

Palatin Technologies (Palatin) is a biopharmaceutical company that develops receptor specific peptide therapeutics. The company’s medicines are based on molecules that control the activity of the melanocortin and natriuretic peptide receptor systems. Its lead product includes Vyleesi, indicated for the treatment of premenopausal women with hypoactive sexual desire disorder. Palatin clinical pipeline includes melanocortin receptor programs such as PL-8177 MC1r Agonist (oral) for inflammatory bowel disease; PL9643 MCr Agonist for dry eye diseases; PL-8177 MC1r Agonist (systemic) for Covid-19 infection; and MC4r Agonist for diabetic retinopathy. Its natriuretic peptide receptor programs include PL-3994 NPR-A for heart failure and PL-5028 NPR-A/C Agonist for heart failure and fibrosis. Palatin is headquartered in Cranbury, New Jersey, the US.

Quick View PL-8177 LOA Data

Report Segments
  • Innovator
Drug Name
  • PL-8177
Administration Pathway
  • Oral
  • Subcutaneous
Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Genito Urinary System And Sex Hormones
  • Immunology
  • Infectious Disease
  • Metabolic Disorders
  • Ophthalmology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.